AI Assistant
Blog
Pricing
Log In
Sign Up
A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.
